术后放疗改善EGFR野生型pN2非鳞非小细胞肺癌完全切除后的无病生存:倾向评分匹配分析
本研究回顾性分析了2006至2019年间566例完全切除后接受辅助化疗或EGFR酪氨酸激酶抑制剂治疗且检测了EGFR状态的pN2非鳞非小细胞肺癌患者,按EGFR状态和是否接受术后放疗分为四组,采用倾向评分匹配平衡基线特征。结果显示,在EGFR野生型患者中,术后放疗组的中位无病生存期为33.9个月,非术后放疗组为17.2个月(HR 0.62,95%CI 0.417-0.920,P=0.017),且局部区域无复发生存和无远处转移生存均改善;在EGFR突变患者中,术后放疗仅改善局部区域无复发生存(HR 0.50,95%CI 0.30-0.85,P=0.009),无病生存和无远处转移生存无显著差异。作者认为,对于完全切除的pN2非鳞非小细胞肺癌接受辅助化疗的患者,术后放疗可能改善EGFR野生型患者的无病生存,但对EGFR突变患者无此作用,需要随机临床试验验证。
要点
- EGFR野生型pN2非鳞非小细胞肺癌完全切除后,术后放疗组中位无病生存33.9个月 vs 非术后放疗组17.2个月(HR 0.62,95%CI 0.417-0.920,P=0.017)。
- EGFR野生型组术后放疗改善局部区域无复发生存(HR 0.58,95%CI 0.34-0.99,P=0.042)和无远处转移生存(HR 0.649,95%CI 0.43-0.98,P=0.038)。
- EGFR突变组术后放疗仅改善局部区域无复发生存(HR 0.50,95%CI 0.30-0.85,P=0.009),无病生存和无远处转移生存无显著差异。
核心结论
- 对于完全切除的pN2非鳞非小细胞肺癌接受辅助化疗的患者,术后放疗可能改善EGFR野生型患者的无病生存,但对EGFR突变患者无此作用,需要随机临床试验验证。
研究设计与样本
- 回顾性分析2006年至2019年间连续纳入的566例完全切除后接受辅助化疗或EGFR酪氨酸激酶抑制剂治疗且检测了EGFR状态的pN2非鳞非小细胞肺癌患者。
- 按EGFR状态和是否接受术后放疗分为四组:EGFR野生型术后放疗组90例、EGFR野生型非术后放疗组154例、EGFR突变术后放疗组111例、EGFR突变非术后放疗组211例。
- 术后放疗采用调强放疗,每次2 Gy,总剂量50 Gy,5周完成。
- 采用倾向评分匹配补偿基线特征差异,用Kaplan-Meier法和log-rank检验评估无病生存、局部区域无复发生存和无远处转移生存。
主要发现
- 倾向评分匹配后,EGFR野生型术后放疗组 vs 非术后放疗组中位无病生存期分别为33.9个月 vs 17.2个月(HR 0.62,95%CI 0.417-0.920,P=0.017)。
- EGFR野生型组中,术后放疗改善局部区域无复发生存(HR 0.58,95%CI 0.34-0.99,P=0.042)和无远处转移生存(HR 0.649,95%CI 0.43-0.98,P=0.038)。
- EGFR突变组中,术后放疗仅改善局部区域无复发生存(HR 0.50,95%CI 0.30-0.85,P=0.009),术后放疗组与非术后放疗组无病生存和无远处转移生存无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ADAURA study indicated that adjuvant TKI therapy improves survival in postoperative patients with EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC), especially in stage III disease. However, the effect of PORT for stage III (N2) NSCLC with different EGFR statuses remains unclear, which we aimed to investigate in the present study. METHODS: Between 2006 and 2019, consecutive patients with pN2 non-squamous cell NSCLC (Nsq-NSCLC) after complete resection and adjuvant chemotherapy or EGFR tyrosine kinase inhibitor (TKI) who had detection of EGFR status were retrospectively analyzed. PORT was administered using IMRT at 2 Gy per fraction with a total dose of 50 Gy over 5 weeks. Patients were categorized into 4 groups according to EGFR status and treatment: EGFR wild-type (EGFRwt) PORT group, EGFRwt non-PORT group, EGFRm PORT group, and EGFRm non-PORT group. Propensity score matching (PSM) was used to compensate for differences in baseline characteristics. The Kaplan-Meier method and log-rank test were used to evaluate disease-free survival (DFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS). RESULTS: A total of 566 patients were enrolled: 90 in the EGFRwt PORT group, 154 in the EGFRwt non-PORT group, 111 in the EGFRm PORT group, and 211 in the EGFRm non-PORT group. After PSM, the median DFS in the EGFRwt PORT group versus the EGFRwt non-PORT group were 33.9 versus 17.2 months (HR 0.62, 95%CI 0.417-0.920, P = 0.017). In EGFRwt groups, PORT also improved LRFS (HR 0.58, 95%CI 0.34-0.99, P = 0.042) and DMFS (HR 0.649, 95%CI 0.43-0.98, P = 0.038). In EGFRm groups, PORT only improved LRFS (HR 0.50, 95%CI 0.30-0.85, P = 0.009), with no significant difference in DFS or DMFS between the PORT and non-PORT groups. CONCLUSION: For patients with completely resected pN2 Nsq-NSCLC receiving adjuvant chemotherapy, PORT may improve DFS in EGFRwt patients but not in EGFRm patients. Randomized clinical trials are needed for validation.
引用
- Liu Y, Men Y, Yang X, et al. Postoperative radiotherapy improves disease-free survival of EGFR wild-type pN2 non-squamous-cell non-small-cell lung cancer (Nsq-NSCLC) patients after complete resection: a propensity score matching analysis. Radiat Oncol. 2025. PMID: 40082994. doi:10.1186/s13014-025-02592-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。